First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study
In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo/bev and durva/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.
Authors
- Amit Mahipal (ORCID: https://orcid.org/0000-0002-1111-8333)
- Gregory James Gores (ORCID: https://orcid.org/0000-0003-3151-009X)
- Michael Torbenson (ORCID: https://orcid.org/0000-0002-8334-7725)
- Patrick P. Starlinger (ORCID: https://orcid.org/0000-0002-4666-5337)
- Robert R. McWilliams (ORCID: https://orcid.org/0000-0002-8199-5040)
- Mitesh J. Borad (ORCID: https://orcid.org/0000-0003-2700-2658)
- Suneel D. Kamath (ORCID: https://orcid.org/0000-0003-0117-366X)
- Wen Wee Ma (ORCID: https://orcid.org/0000-0001-5899-4034)
- Nguyen H. Tran (ORCID: https://orcid.org/0000-0001-7323-9213)
- Soo Young Hwang (ORCID: https://orcid.org/0000-0001-9845-7073)
- Leslie Washburn
- Pin‐Jung Chen (ORCID: https://orcid.org/0000-0002-5923-5299)
- Lewis R. Roberts (ORCID: https://orcid.org/0000-0001-7885-8574)
- Nicole Peterson (ORCID: https://orcid.org/0009-0000-6035-4124)
- Garima Gupta (ORCID: https://orcid.org/0000-0002-8730-006X)
- Paulina S. Marell (ORCID: https://orcid.org/0000-0003-4225-3922)
- Aminah Jatoi (ORCID: https://orcid.org/0000-0002-1081-189X)
- Hani M. Babiker (ORCID: https://orcid.org/0000-0002-9368-6296)
- Jennifer Gile (ORCID: https://orcid.org/0000-0001-6972-7986)
- Daniel H. Ahn (ORCID: https://orcid.org/0000-0002-0161-4018)
- Nikolas Naleid (ORCID: https://orcid.org/0009-0005-3297-1041)
- Sudhakar K. Venkatesh (ORCID: https://orcid.org/0000-0002-7514-1030)
- Ioannis Kournoutas (ORCID: https://orcid.org/0009-0001-5260-8187)
- Fang‐Shu Ou (ORCID: https://orcid.org/0000-0003-1267-8735)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Kyle VanDommelen
- Vaibhav Sahai (ORCID: https://orcid.org/0000-0003-1892-1548)
- Ajit H. Goenka (ORCID: https://orcid.org/0000-0002-7804-2695)
- Priyanshi Shah (ORCID: https://orcid.org/0000-0002-1537-2726)
- Mehmet Akce (ORCID: https://orcid.org/0000-0003-4747-7722)
- Scott A. Thompson (ORCID: https://orcid.org/0000-0002-8048-9226)
- Caitlin B. Conboy (ORCID: https://orcid.org/0000-0001-8280-056X)
- Anina Peersen
- Zhaohui Jin (ORCID: https://orcid.org/0000-0001-7844-5833)
- Thorvardur Halfdanarson
- Lionel Fonkoua Kankeu
Institutions
- Cedars-Sinai Medical Center (US)
- Cleveland Clinic (US)
- Mayo Clinic (US)
- University of Alabama at Birmingham Hospital (US)
- University of Michigan (US)
- Alliance for Clinical Trials in Oncology (US)
- Jacksonville College (US)
- University of Alabama at Birmingham (US)
- Michigan Medicine (US)
- University Hospitals Seidman Cancer Center (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1093/oncolo/oyaf286
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64